Created On: 2020-07-15
Record Count: 3
- Technical Know How
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2012
IPSCIO Record ID: 195780
Licensor owns the rights to Patent Application Serial No. 62/478520 filed 03-29-17 â€œMethods of Re-Activating Dormant Memory Cells with Anticancer Activityâ€ and commercially named â€œMemoryMuneâ€.
The patent licensed provides means to recapitulate a natural immune response ex vivo through activation of innate immune cells, and subsequently utilizing products generated by said cells to stimulate adaptive immune cells to acquire ability to induce killing or inhibiting proliferation of cells expressing oncogenic transformations. In one embodiment of the invention, innate immune cells are activated with stimuli capable of inducing production of cytokines associated with induction of immunity to intracellular abnormalities; said cytokines are further administered to adaptive immune cells in a patient in need of treatment.
Licensee intends to develop products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.
Developing the novel immunological use of mifepristone in the area of oncology adds another weapon in the fight against cancer using the patientâ€™s own immune system. Natural killer cells are a unique arm of the immune system that is capable of killing cancer cells without prior sensitization. The findings that mifepristone is capable of reducing cancer associated suppression of the natural killer cell compartment, we believe, positions mifepristone as a potentially valuable therapeutic in utilization of the immune system to kill tumors.
IPSCIO Record ID: 275802
Xcellerateâ„¢ Technology means the Licensor Patents and Licensor Know-How.
Licensor Patents means, to the extent owned or Controlled by Licensor, or owned or Controlled jointly by Licensor and Licensee:
6,352,694 – Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
5,858,358 – Methods for selectively stimulating proliferation of T cells
5,883,223 – CD9 antigen peptides and antibodies thereto
Licensor Know-How means any and all technical information, processes, formulae, data, engineering, inventions, chemical compounds, know-how and trade secrets owned or Controlled by Licensor that relate to the Xcellerated T Cellsâ„¢, Xcellerateâ„¢ II Process and the Xcellerateâ„¢ III Process and any other proprietary information.
Xcellerated T Cellsâ„¢â€ means the T cells that are produced by the use of the Xcellerateâ„¢ Technology, including but not limited to the use of the Licensor DynabeadsÂ®, Xcellerateâ„¢ II Process or Xcellerateâ„¢ III Process or derivatives thereof.
Xcellerateâ„¢ II Processâ€ means a static process configuration as it exists as of the Effective Date and is defined in Xcyte Therapies Master Production Records MPR 11-0002 & 11-0005 submitted to FDA on September 19, 2001.
Xcellerateâ„¢ III Process means the process configuration based on the WaveBioreactor as it exists as of the Effective Date and is defined in Licensor Therapies Master Production Records MPR 11-0006 & 11-0007 submitted to the FDA on May 15, 2003.
Licensor DynabeadsÂ®â€ means XR-CD3 and XR-CD28 antibodies produced at Lonza Biologics that are conjugated to super-paramagnetic Dynaspheres MS-4.5-REK particles at Dynal Biotech A.S.A.